Why the study?
Does the Micra leadless VVI pacemaker reduce reinterventions and chronic complications compared to transvenous VVI pacing in US Medicare patients?
Population
US Medicare patients
Comparison
Micra leadless VVI pacemaker vs transvenous VVI pacing
Design
Real-world study
Follow-up
2 years
Authors
Loading...
May support leadless VVI preference in Medicare patients; extends observational data but leaves open randomized confirmation.
Does the Micra leadless VVI pacemaker reduce reinterventions and chronic complications compared to transvenous VVI pacing in US Medicare patients?
In a real-world Medicare population, leadless VVI pacing significantly reduced reinterventions and chronic complications compared to transvenous pacing at 2 years, without affecting mortality.
El‐Chami et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: